Effects of growth hormone treatment after final height in Prader-Willi Syndrome

Not Applicable

Completed

• Conditions: Prader Willi Syndrome; Nutritional, Metabolic, Endocrine; Disorders of other endocrine glands

• Registration Number: ISRCTN24648386
• Lead Sponsor: Dutch Growth Foundation (Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-09-05
• Last Update Posted: 19 December 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Young adults, originally participating in the Dutch GH study in PWS children (ISRCTN49726762) or otherwise GH-treated patients
2. Final height is reached or epiphysial fusion is complete
3. Treated with GH during childhood for at least two years

Exclusion Criteria

1. Non-cooperative behaviour
2. Extremely low dietary intake of less than minimal required intake according to World Health Organisation (WHO)
3. Medication to reduce weight (fat)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Body composition<br>2. Carbohydrate metabolism<br>3. Psychosocial functioning<br>4. Sleep-related breathing disorders<br>5. Circulating lipids<br>6. Blood pressure

Secondary Outcome Measures

Name	Time	Method
1. Thyroid hormone levels, Insulin-like Growth Factor (IGF-I) and IGF binding proteins, adiponectin, ghrelin<br>2. Compliance to the diet